https://www.reuters.com/article/health-coronavirus-southkorea-celltrion-idUSKBN27B07V

16 0

FILE PHOTO: The logo of Celltrion is seen at company's headquarters in Incheon, South Korea, October 28, 2016. REUTERS/Kim Hong-Ji/File photo. SEOUL (Reuters) - South Korea’s Celltrion Inc said on Monday it has received emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates. Celltrion said Sampinute delivers coronavirus test results within 10 minutes, with a sensitivity of around 94%. The authorisation came three months after requesting approval in late July and the product has already been launched in the United States in August, according to the company statement. “(The company) is planning to supply Sampinute across the United States through local wholesalers as it believes the demand for rapid diagnosis kits will be high, mainly among large businesses and government agencies that are about to return to work after telecommuting,” it said in a statemen... ... Full story

26 October

wait